What's The BUZZ?

Market News, Products, Services, and Trends

Dr. Reddy’s Laboratories announces the launch of Treprostinil Injection in the U.S.

Hyderabad India; April 21, 2023 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin® (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA).


Dr. Reddy’s Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials.


Please click here to see the full prescribing information: https://www.drreddys.com/pi/150092607-Treprostinil-Injection-Leaflet.pdf


Remodulin® is a registered trademark of United Therapeutics Corporation.

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. News & Announcements

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

10-rxinsider-staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

This post is related to:

SUBSCRIBE

Please enable JavaScript in your browser to complete this form.
Name
Subscription Choices
Checkboxes

Request information from Dr. Reddy’s Laboratories announces the launch of Treprostinil Injection in the U.S.

Please enable JavaScript in your browser to complete this form.
Name
Address
Subscribe